Skip to main content
SpringerLink
Log in

The Challenges of Interstitial Cystitis: Current Status and Future Prospects

  • Current Opinion
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a syndrome of unpleasant bladder sensations and lower urinary tract symptoms. The three main proposed etiologies are bladder urothelial dysfunction, bladder inflammation (possible neurogenic), and neuropathic pain. Despite decades of basic and clinical research, IC/BPS remains difficult to treat. A variety of treatments are used, each aimed towards one etiology. For example, glycosaminoglycans are thought to improve the urothelial permeability barrier, anti-inflammatory agents are used to decrease general inflammation, and mast cell stabilizers and/or antagonists of mast cell products are used in the treatment of neurogenic inflammation. In the (unfortunately frequent) event that a treatment fails, possible reasons are that (1) the clinician is aiming towards the wrong etiology for that patient (i.e., the treatment is off target) or (2) the correct etiology is being targeted, but the treatment is not ameliorating it (i.e., the treatment is sub-therapeutic). This is a crucial distinction, because an off-target treatment should be abandoned, but a sub-therapeutic treatment should be escalated. Currently, our inability to make this crucial distinction is the greatest obstacle to effective treatment. An important future advance would be to identify urine or serum biomarkers specific to each etiologic target. Then, each biomarker could be used to select appropriate patients for each treatment and monitor the treatment’s effect on its intended target.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hanno PM, Erickson D, Moldwin R, Faraday MM. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol. 2015;193(5):1545–53.

    Article  PubMed  Google Scholar 

  2. van de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, Cervigni M, Daha LK, Elneil S, Fall M, Hohlbrugger G, Irwin P, Mortensen S, van Ophoven A, Osborne JL, Peeker R, Richter B, Riedl C, Sairanen J, Tinzl M, Wyndaele JJ. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008;53(1):60–7.

    Article  PubMed  Google Scholar 

  3. Homma Y, Ueda T, Ito T, Takei M, Tomoe H. Japanese guideline for diagnosis and treatment of interstitial cystitis. I Int J Urol. 2009;16(1):4–16.

    Article  PubMed  Google Scholar 

  4. Keay SK, Zhang CO, Shoenfelt J, Erickson DR, Whitmore K, Warren JW, Marvel R, Chai T. Sensitivity and specificity of antiproliferative factor, heparin-binding epidermal growth factor-like growth factor, and epidermal growth factor as urine markers for interstitial cystitis. Urology. 2001;57(6 Suppl 1):9–14.

    Article  CAS  PubMed  Google Scholar 

  5. Parsons CL, Shaw T, Berecz Z, Su Y, Zupkas P, Argade S. Role of urinary cations in the aetiology of bladder symptoms and interstitial cystitis. BJU Int. 2014;114(2):286–93.

    Article  CAS  PubMed  Google Scholar 

  6. Rubio-Diaz DE, Pozza ME, Dimitrakov J, Gilleran JP, Guisti MM, Stella JL, Rodriguez-Saona LE, Buffington CA. A candidate serum biomarker for bladder pain syndrome/interstitial cystitis. Analyst. 2009;134(6):1133–7.

  7. Nickel JC, Herschorn S, Whitmore KE, Forrest JB, Hu P, Friedman AJ, Baseman AS. Pentosan polysulfate sodium for treatment of interstitial cystitis/bladder pain syndrome: insights from a randomized, double-blind, placebo controlled study. J Urol. 2015;193(3):857–62.

    Article  CAS  PubMed  Google Scholar 

  8. Hwang P, Auclair B, Beechinor D, Diment M, Einarson TR. Efficacy of pentosan polysulfate in the treatment of interstitial cystitis: a meta-analysis. Urology. 1997;50(1):39–43.

    Article  CAS  PubMed  Google Scholar 

  9. Parsons CL, Koziol JA, Proctor JG, Zupkas P, Argade S. Heparin and alkalinized lidocaine versus alkalinized lidocaine for treatment of interstitial cystitis symptoms. Can J Urol. 2015;22(2):7739–44.

    PubMed  Google Scholar 

  10. Hanno PM. Painful bladder syndrome (Interstitial Cystitis) and related disorers. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh Urology. 10th ed. Philadelphia; 2012. p. 470–537.

  11. Chintea CL, Belal M. Is there enough evidence for the use of intravesical instillations of glycosaminoglycan analogues in interstitial cystitis? BJU Inj. 2013;111(2):192–3.

    Article  Google Scholar 

  12. Nickel JC, Hanno P, Kumar K, Thomas H. Second multicenter, randomized, double-blind, parallel-group evaluation of effectiveness and safety of intravesical sodium chondroitin sulfate compared with inactive vehicle control in subjects with interstitial cystitis/bladder pain syndrome. Urology. 2012;79(6):1220–4.

    Article  PubMed  Google Scholar 

  13. Chuang YC, Lee WC, Chiang PH. Intravesical liposome versus oral pentosan polysulfate for interstitial cystitis/painful bladder syndrome. J Urol. 2009;182(4):1393–400.

    Article  CAS  PubMed  Google Scholar 

  14. Lander EB, See JR. Intravesical instillation of pentosan polysuflate encapsulated in a liposome nanocarrier for interstitial cystitis. Am J Clin Exp Urol. 2014;2(2):145–8.

    PubMed Central  PubMed  Google Scholar 

  15. Wilkinson D and Erickson DR. Urinary and serologic markers for interstitial cystitis: an update. Curr Urol Rep. 2006;7(5):414–22.

  16. Parsons CL, Forrest J, Nickel JC, Evans R, Lloyd LK, Barkin J, Mosbaugh PG, Kaufman DM, Hernandez-Graulau JM, Atkinson L, Albrecht D. Effect of pentosan polysulfate therapy on intravesical potassium sensitivity. Urology. 2002;59(3):329–33.

    Article  PubMed  Google Scholar 

  17. Gupta SK, Pidcock L, Parr NJ. The potassium sensitivity test: a predictor of treatment response in interstitial cystitis. BJU. 2005;96(7):1063–6.

    Article  CAS  Google Scholar 

  18. Keay SK, Birder LA, Chai TC. Evidence for bladder urothelial pathophysiology in functional bladder disorders. Biomed Res Int. 2014;2014:86543.

    Article  Google Scholar 

  19. Forrest JB, Payne CK, Erickson DR. Cyclosporine A for refractory interstitial cystitis/bladder pain syndrome: experience of 3 tertiary centers. J Urol. 2012;188(4):1186–91.

    Article  CAS  PubMed  Google Scholar 

  20. Soucy F, Gregoire M. Efficacy of prednisone for severe refractory ulcerative interstitial cystitis. J Urol. 2005;173(3):841–3.

    Article  CAS  PubMed  Google Scholar 

  21. Hosseini A, Ehren I, Wiklund NP. Nitric oxide as an objective marker for evaluation of treatment response in patients with classic interstitial cystitis. J Urol. 2004;172(6 Pt 1):2261–5.

    Article  CAS  PubMed  Google Scholar 

  22. Cetinel S, Cetinel BI, Ercan F, Hrda C, San T. Indomethacin-induced morphologic changes in the rat urinary bladder epithelium. Urology. 2003;61(1):236–42.

    Article  PubMed  Google Scholar 

  23. Schou J, Jensen HL, Frimodt-Moller C. Interstitial cystitis provoked by tiaprofenic acid. Scand J Urol Nephrol. 1999;33(6):411–2.

    Article  CAS  PubMed  Google Scholar 

  24. Sant GR, Theoharides TC. The role of the mast cell in interstitial cystitis. Urol Clin North Am. 1994;21(1):41–53.

    CAS  PubMed  Google Scholar 

  25. Wyndaele JJ, Van Dyck J, Toussaint N. Cystoscopy and bladder biopsies in patients with bladder pain syndrome carried out following ESSIC guidelines. Scand J Urol Nephrol. 2009;43(6):471–5.

    Article  PubMed  Google Scholar 

  26. Van der Aa F, Beckley I, de Ridder D. Polyomavirus BK: a potential new therapeutic target for painful bladder syndrome/interstitial cystitis? Med Hypotheses. 2014;83(3):317–20.

    Article  PubMed  Google Scholar 

  27. Erickson DR, Tomaszewski JE, Kunselman AR, Setter CM, Peters KM, Rovner ES, Demers LM, Wheeler MA, Keay SK. Urine markers do not predict biopsy findings or presence of bladder ulcers in interstitial cystitis/painful bladder syndrome. J Urol. 2008;179(5):1850–6.

    Article  PubMed Central  PubMed  Google Scholar 

  28. Kuo HC. Potential urine and serum biomarkers for patients with bladder pain syndrome/interstitial cystitis. Int J Urol. 2014;21(Suppl 1):34–41.

    Article  PubMed  Google Scholar 

  29. Henry RA, Morales A, Cahill CM. Beyond a simple anesthetic effect: lidocaine in the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. Urology. 2015;85(5):1025–33.

    Article  PubMed  Google Scholar 

  30. Thilagarajah R, Witherow RO, Walker MM. Oral cimetidine gives effective symptom relief in painful bladder disease: a prospective, randomized, double-blind placebo-controlled trial. BJU Int. 2001;87(3):207–12.

    Article  CAS  PubMed  Google Scholar 

  31. Chiang G, Patra P, Letourneau R, Jeudy S, Boucher W, Green M, Sant GR, Theoharides TC. Pentosanpolysulfate (Elmiron) is a potent inhibitor of mast cell histamine secretion. Adv Exp Med Biol. 2003;539(Pt B):713–29.

  32. Edwards L, Bucknall TE, Makin C. Interstitial cystitis: possible cause and clinical study of sodium cromoglycate. Br J Urol. 1986;58(1):95–6.

    Article  CAS  PubMed  Google Scholar 

  33. Theoharides TC, Sant GR. A pilot open label study of cystoprotek in interstitial cystitis. Int J Immunopathol Pharmacol. 2005;18(1):183–8.

  34. Kuo HC, Jiang YH, Tsai YC, Kuo YC. Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis/bladder pain syndrome refractory to conventional treatment: a prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. Neurourol Urodyn. 2015. doi:10.1002/nau.22760 [Epub ahead of print].

  35. Cole EE, Scarpero HM, Dmochowski RR. Are patient symptoms predictive of the diagnostic and/or therapeutic value of hydrodistention? Neurourol Urodyn. 2005;24(7):638–42.

    Article  PubMed  Google Scholar 

  36. Erickson DR, Simon LJ, Belchis DA. Relationships between bladder inflammation and other clinical features in interstitial cystitis. Urology. 1994;44(5):655–9.

    Article  CAS  PubMed  Google Scholar 

  37. Lynes WL, Flynn SD, Shortliffe LD, Stamey TA. The histology of interstitial cystitis. Am J Surg Path. 1990;14:969.

    Article  CAS  PubMed  Google Scholar 

  38. Yun SK, Laub DJ, Weese DL, Lad PM, Leach GE, Zimmern PE. Stimulated release of urine histamine in interstitial cystitis. J Urol. 1992;148(4):1145–8.

    CAS  PubMed  Google Scholar 

  39. Erickson DR, Kunselman AR, Bentley CM, Peters KM, Rovner ES, Demers LM, Wheeler MA, Keay SK. Changes in urine markers and symptoms after bladder distention for interstitial cystitis. J Urol. 2007;177(2):556–60.

    Article  PubMed Central  PubMed  Google Scholar 

  40. Marchand JE, Sant GR, Kream RM. Increased expression of substance P receptor-encoding mRNA in bladder biopsies from patients with interstitial cystitis. Br J Urol. 1998;81(2):224–8.

    Article  CAS  PubMed  Google Scholar 

  41. Farmer MA, Huang L, Martucci K, Yang CC, Maravilla KR, Harris RE, Clauw DJ, Mackey S, Ellingson BM, Mayer EA, Schaeffer AJ, Apkarian AV, MAPP Research Network. Brain white matter abnormalities in female interstitial cystitis/bladder pain syndrome: a MAPP network neuroimaging study. J Urol. 2015;194(1):118–26.

    Article  PubMed Central  PubMed  Google Scholar 

  42. Kilpatrick LA, Kutch JJ, Tillisch K, Naliboff BD, Labus JS, Jiang Z, Farmer MA, Apkarian AV, Mackey S, Martucci KT, Clauw DJ, Harris RE, Deutsch G, Ness TJ, Yang CC, Maravilla K, Mullins C, Mayer EA. Alterations in resting state oscillations and connectivity in sensory and motor networks in women with interstitial cystitis/painful bladder syndrome. J Urol. 2014;192(3):947–55.

    Article  PubMed Central  PubMed  Google Scholar 

  43. Ness TJ, Lloyd LK, Fillingim RB. An endogenous pain control system is altered in subjects with interstitial cystitis. J Urol. 2014;191(2):364–70.

    Article  PubMed  Google Scholar 

  44. Gilron I, Baron R, Jensen T. Neuropathic pain: principles of diagnosis and treatment. Mayo Clin Proc. 2015;90(4):532–45.

    Article  CAS  PubMed  Google Scholar 

  45. Foster HE Jr, Hanno PM, Nickel JC, Payne CK, Mayer RD, Burks DA, Yang CC, Chai TC, Kreder KJ, Peters KM, Lukacz ES, FitzGerald MP, Cen L, Landis JR, Propert KJ, Yang W, Kusek JW, Nyberg LM, Interstitial Cystitis Collaborative Research Network. Effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome. J Urol. 2010;183(5):1853–8.

    Article  PubMed Central  PubMed  Google Scholar 

  46. van Ophoven A, Pokupic S, Heinecke A, Hertle L. A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis. J Urol. 2004;172(2):533–6.

    Article  PubMed  Google Scholar 

  47. van Ophoven A, Hertle L. The dual serotonin and noradrenaline reuptake inhibitor duloxetine for the treatment of interstitial cystitis: results of an observational study. J Urol. 2007;177(2):552–5.

    Article  PubMed  Google Scholar 

  48. Moulin D, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA, Furlan A, Gilron I, Gordon A, Morley-Forster PK, Sessle BJ, Squire P, Stinson J, Taenzer P, Velly A, Ware MA, Weinberg EL, Williamson OD. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014;19(6):328–35.

  49. Collins VM, Daly DM, Liaskos M, McKay NG, Sellers D, Chapple C, Grundy D. OnabotulinumtoxinA significantly attenuates bladder afferent nerve firing and inhibits ATP release from the urothelium. BJU Int. 2013;112(7):1018–26.

    CAS  PubMed  Google Scholar 

  50. Kuo HC, Chancellor MB. Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int. 2009;104(5):657–61.

    Article  CAS  PubMed  Google Scholar 

  51. Cruz CD. Neurotrophins in bladder function: what do we know and where do we go from here? Neurourol Urodyn. 2014;33(1):39–45.

    Article  CAS  PubMed  Google Scholar 

  52. McKlevey L, Shorten GD, O’Keefe GW. Nerve growth factor-mediated regulation of pain signaling and proposed new intervention strategies in clinical pain management. J Neurochem. 2013;124(3):276–89.

    Article  Google Scholar 

  53. Lowe EM, Anand P, Terenghi G, Williams-Chestnut RE, Sinicropi DV, Osborne JL. Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. Br J Urol. 1997;79(4):572–7.

    Article  CAS  PubMed  Google Scholar 

  54. Liu HT, Kuo HC. Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis. Urology. 2007;70(3):463–8.

    Article  PubMed  Google Scholar 

  55. Liu BL, Yang F, Zhan HL, Feng ZY, Zhang ZG, Li WB, Zhou XF. Increased severity of inflammation correlates with elevated expression of TRPV1 nerve fibers and nerve growth factor on interstitial cystitis/bladder pain syndrome. Urol Int. 2014;92(2):202–8.

    Article  CAS  PubMed  Google Scholar 

  56. Qu HC, Zhang W, Yan S, Liu YL, Wang P. Urinary nerve growth factor could be a biomarker for interstitial cystitis/painful bladder syndrome: a meta-analysis. PLoS One. 2014;9(9):e106321.

    Article  PubMed Central  PubMed  Google Scholar 

  57. Jacobs BL, Smaldone MC, Tyagi V, Phillips BJ, Jackman SV, Leng WW, Tyagi P. Increased nerve growth factor in neurogenic overactive bladder and interstitial cystitis patients. Can J Urol. 2010;17(1):4989–94.

    PubMed  Google Scholar 

  58. Kuo HC, Liu HT, Tyagi P, Chancellor M. Urinary nerve growth factor levels in urinary Tract disease with or without frequency urgency symptoms. LUTS. 2010;2:88–94.

    CAS  Google Scholar 

  59. Gamper M, Moser R, Viereck V. Have we been led astray by the NGF biomarker data? Neurourol Urodyn. 2015. doi:10.1002/nau.22882 [Epub ahead of print].

  60. Siddiqui H, Lagesen K, Nederbragt AJ, Jeansson SL, Jakobsen KS. Alterations of microbiota in urine from women with interstitial cystitis. BMC Microbiol. 2012;13(12):205.

    Article  Google Scholar 

  61. Winter BJ, O’Connell HE, Bowden S, Carey M, Eisen DP. A case control study reveals that polyomaviruria is significantly associated with interstitial cystitis and vesical ulceration. PLoS One. 2015;10(9):e0137310.

    Article  PubMed Central  PubMed  Google Scholar 

  62. Yoshimura N, Oguchi T, Yokoyama H, Funahashi Y, Yoshikawa S, Sugino Y, Kawamorita N, Kashyap MP, Chancellor MB, Tyagi P, Ogawa T. Bladder afferent hyperexcitability in bladder pain syndrome/interstitial cystitis. Int J Urol. 2014;21(Suppl 1):18–25.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Kentucky College of Medicine, 800 Rose St., MS-269, Lexington, KY, 40536-0298, USA

    Samuel Belknap & Deborah Erickson

  2. Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, KY, USA

    Eric Blalock

Authors
  1. Samuel Belknap
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric Blalock
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Deborah Erickson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Samuel Belknap.

Ethics declarations

Funding

Samuel Belknap, Eric Blalock, and Deborah Erickson have no sources of funding related to this paper to disclose.

Conflict of interest

Samuel Belknap, Eric Blalock, and Deborah Erickson have no conflicts of interest to disclose.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Belknap, S., Blalock, E. & Erickson, D. The Challenges of Interstitial Cystitis: Current Status and Future Prospects. Drugs 75, 2057–2063 (2015). https://doi.org/10.1007/s40265-015-0504-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-015-0504-9

Keywords

Search

Navigation